# NIH grant: Cost Offsets and Spending on Glucagon-like peptide-1 receptor agonists (GLP-1s) in a Large National Electronic Health Record Database (1R01DK144049-01A1) — retained record

> Retained us-gov-api record from us-gov-api:nih-reporter.

Canonical: https://highsignal.app/data/records/a59cf759131f0e1a

[← sources](https://highsignal.app/data)


source: [us-gov-api](https://highsignal.app/data/us-gov-api) (us-gov-api:nih-reporter)  published 2026-07-10 00:00 ingested 2026-07-13 09:04

[original source ↗](https://reporter.nih.gov/project-details/1R01DK144049-01A1)

## retained text



```
NIH grant 1R01DK144049-01A1: Cost Offsets and Spending on Glucagon-like peptide-1 receptor agonists (GLP-1s) in a Large National Electronic Health Record Database
Institute: {'code': 'DK', 'abbreviation': 'NIDDK', 'name': 'National Institute of Diabetes and Digestive and Kidney Diseases', 'admin_org_id': '12500020', 'admin_funding_url': ''}. PI: Joseph Frank Levy. Award: $766545.
Start: 2026-07-10T00:00:00.
Abstract
Obesity and overweight impose significant clinical and economic burdens, impacting over 64% of U.S. adults,
leading to healthcare costs exceeding $170 billion annually. This project focuses on glucagon-like peptide-1
receptor agonists (GLP-1s), first approved for weight loss in 2021, a promising treatment for obesity that not
only induces substantial weight loss but also improves metabolic conditions such as cardiovascular disease
and diabetes. Despite their effectiveness, the high cost of GLP-1s, over $7,000 per year, has resulted in limited
insurance coverage, thereby restricting patients' ability to access these potentially transformational medicines.
The central objective of this research is to determine if GLP-1 therapy can offset their high costs by reducing
overall healthcare spending for patients who initiate treatment. Clinical trials show the clinical benefits of GLP-
1s but have limitations, including no established link between weight loss with GLP-1s and healthcare
spending and short follow-up periods that make it difficult to assess long-term outcomes. By leveraging a large
national dataset, Truveta, which contains Electronic Health Records for over 100 million patients, linked with
insurance claims, the study aims to provide much-needed long-term evidence on spending. We will leverage
state-of-the-art matching, and real-world evidence methods to achieve three key aims: (1) evaluating long-term
cost offsets and medication costs after GLP-1 initiation, (2) assessing how these costs vary across patient
subgroups defined by characteristics like BMI, age, and comorbidities, and (3) estimating the GLP-1 breakeven
price and the time required to achieve budget neutrality. These findings will inform insurers and policymakers,
contributing to future coverage and reimbursement decisions, with significant implications for Medicare,
Medicaid, and private insurers. The project directly responds to calls from the Congressional Budget Office and
other key stakeholders for more research on the economic impact of GLP-1 therapies.
```



document fetched 2026-07-19 08:08